Laboratory Medicine ›› 2018, Vol. 33 ›› Issue (9): 775-780.DOI: 10.3969/j.issn.1673-8640.2018.09.001
ZHANG Lihua1, WANG Weiwei1, ZHANG Liang2(), SHEN Lisong1
Received:
2017-10-14
Online:
2018-09-30
Published:
2018-10-13
CLC Number:
ZHANG Lihua, WANG Weiwei, ZHANG Liang, SHEN Lisong. Role of monocytic HLA-DR and CD16 determinations in inflammatory diseases[J]. Laboratory Medicine, 2018, 33(9): 775-780.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2018.09.001
组别 | 例数 | NEUT#(×109/L) | NEUT% (%) | LYMPH#(×109/L) | LYMPH%(%) | NLR | MO# (×109/L) | MO% (%) |
---|---|---|---|---|---|---|---|---|
炎症性疾病组 | 56 | 9.68 ± 4.27* | 82.25 ± 7.08* | 1.04 ± 0.50* | 9.83 ± 4.63* | 10.79 ± 6.12* | 0.77 ± 0.33* | 7.02 ± 3.44 |
正常对照组 | 40 | 3.45 ± 0.88 | 58.09 ± 5.94 | 1.93 ± 0.38 | 33.23 ± 6.05 | 1.86 ± 0.64 | 0.36 ± 0.09 | 6.09 ± 1.27 |
组别 | 例数 | NEUT#(×109/L) | NEUT% (%) | LYMPH#(×109/L) | LYMPH%(%) | NLR | MO# (×109/L) | MO% (%) |
---|---|---|---|---|---|---|---|---|
炎症性疾病组 | 56 | 9.68 ± 4.27* | 82.25 ± 7.08* | 1.04 ± 0.50* | 9.83 ± 4.63* | 10.79 ± 6.12* | 0.77 ± 0.33* | 7.02 ± 3.44 |
正常对照组 | 40 | 3.45 ± 0.88 | 58.09 ± 5.94 | 1.93 ± 0.38 | 33.23 ± 6.05 | 1.86 ± 0.64 | 0.36 ± 0.09 | 6.09 ± 1.27 |
组别 | 例数 | HLA-DR MFI | HLA-DR+%(%) | HLA-DR+MFI | CD16 MFI | CD16+ %(%) | CD16+MFI |
---|---|---|---|---|---|---|---|
炎症性疾病组 | 56 | 1 426 ± 733* | 71.44 ± 21.15* | 1 823 ± 568* | 467 ± 237* | 18.14 ± 13.70* | 3 272 ± 1 753* |
正常对照组 | 40 | 3 805 ± 1 266 | 98.69 ± 2.12 | 3 838 ± 1 250 | 155 ± 48 | 9.59 ± 4.74 | 871 ± 256 |
组别 | 例数 | HLA-DR MFI | HLA-DR+%(%) | HLA-DR+MFI | CD16 MFI | CD16+ %(%) | CD16+MFI |
---|---|---|---|---|---|---|---|
炎症性疾病组 | 56 | 1 426 ± 733* | 71.44 ± 21.15* | 1 823 ± 568* | 467 ± 237* | 18.14 ± 13.70* | 3 272 ± 1 753* |
正常对照组 | 40 | 3 805 ± 1 266 | 98.69 ± 2.12 | 3 838 ± 1 250 | 155 ± 48 | 9.59 ± 4.74 | 871 ± 256 |
项目 | NEUT# | NEUT% | LYMPH# | LYMPH% | NLR | MO# | MO% |
---|---|---|---|---|---|---|---|
HLA-DR MFI | |||||||
r值 | -0.696 | -0.729 | 0.533 | 0.706 | -0.711 | -0.476 | 0.087 |
P值 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | >0.05 |
HLA-DR+% | |||||||
r值 | -0.740 | -0.754 | 0.539 | 0.745 | -0.751 | -0.511 | 0.102 |
P值 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | >0.05 |
HLA-DR+ MFI | |||||||
r值 | -0.649 | -0.688 | 0.489 | 0.650 | -0.657 | -0.427 | 0.104 |
P值 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | >0.05 |
CD16 MFI | |||||||
r值 | 0.503 | 0.505 | -0.469 | -0.556 | 0.549 | 0.499 | 0.174 |
P值 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | >0.05 |
CD16+% | |||||||
r值 | 0.208 | 0.174 | -0.240 | -0.266 | 0.250 | 0.354 | 0.261 |
P值 | <0.05 | >0.05 | <0.05 | <0.01 | <0.05 | <0.01 | <0.05 |
CD16+MFI | |||||||
r值 | 0.603 | 0.652 | -0.553 | -0.646 | 0.645 | 0.531 | 0.131 |
P值 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | >0.05 |
项目 | NEUT# | NEUT% | LYMPH# | LYMPH% | NLR | MO# | MO% |
---|---|---|---|---|---|---|---|
HLA-DR MFI | |||||||
r值 | -0.696 | -0.729 | 0.533 | 0.706 | -0.711 | -0.476 | 0.087 |
P值 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | >0.05 |
HLA-DR+% | |||||||
r值 | -0.740 | -0.754 | 0.539 | 0.745 | -0.751 | -0.511 | 0.102 |
P值 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | >0.05 |
HLA-DR+ MFI | |||||||
r值 | -0.649 | -0.688 | 0.489 | 0.650 | -0.657 | -0.427 | 0.104 |
P值 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | >0.05 |
CD16 MFI | |||||||
r值 | 0.503 | 0.505 | -0.469 | -0.556 | 0.549 | 0.499 | 0.174 |
P值 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | >0.05 |
CD16+% | |||||||
r值 | 0.208 | 0.174 | -0.240 | -0.266 | 0.250 | 0.354 | 0.261 |
P值 | <0.05 | >0.05 | <0.05 | <0.01 | <0.05 | <0.01 | <0.05 |
CD16+MFI | |||||||
r值 | 0.603 | 0.652 | -0.553 | -0.646 | 0.645 | 0.531 | 0.131 |
P值 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | >0.05 |
检测指标 | AUC(95% 可信区间) | 最佳临界值 | 敏感性(%) | 特异性(%) |
---|---|---|---|---|
HLA-DR MFI | 0.944(0.901~0.988) | 2 441.5 | 91.1 | 87.5 |
HLA-DR+ % | 0.944(0.902~0.987) | 95.0% | 85.7 | 95.0 |
HLA-DR+ MFI | 0.924(0.866~0.981) | 2 789.5 | 94.6 | 80.0 |
CD16 MFI | 0.911(0.855~0.967) | 279.5 | 69.6 | 100.0 |
CD16+ % | 0.722(0.623~0.822) | 12.2% | 62.5 | 75.0 |
CD16+ MFI | 0.979(0.959~1.000) | 1 203.0 | 94.6 | 92.5 |
检测指标 | AUC(95% 可信区间) | 最佳临界值 | 敏感性(%) | 特异性(%) |
---|---|---|---|---|
HLA-DR MFI | 0.944(0.901~0.988) | 2 441.5 | 91.1 | 87.5 |
HLA-DR+ % | 0.944(0.902~0.987) | 95.0% | 85.7 | 95.0 |
HLA-DR+ MFI | 0.924(0.866~0.981) | 2 789.5 | 94.6 | 80.0 |
CD16 MFI | 0.911(0.855~0.967) | 279.5 | 69.6 | 100.0 |
CD16+ % | 0.722(0.623~0.822) | 12.2% | 62.5 | 75.0 |
CD16+ MFI | 0.979(0.959~1.000) | 1 203.0 | 94.6 | 92.5 |
[1] | 赵蓉,彭桉平,陈曲波. 炎症性单核细胞亚群在自身免疫性疾病中的研究进展[J]. 中国免疫学杂志,2014,30(3):423-425. |
[2] | LEE J,TAM H,ADLER L,et al.The MHC class Ⅱ antigen presentation pathway in human monocytes differs by subset and is regulated by cytokines[J]. PLoS One,2017,12(8): e0183594. |
[3] | 王鑫,康富标,王桂平,等. CD14+CD16+亚型单核细胞的研究进展[J]. 免疫学杂志,2012,28(10):910-913. |
[4] | ZIEGLER-HEITBROCK L,ANCUTA P,CROWE S,et al.Nomenclature of monocytes and dendritic cells in blood[J]. Blood,2010,116(16): e74-e80. |
[5] | WONG K L,YEAP W H,TAI J J,et al.The three human monocyte subsets: implications for health and disease[J]. Immunol Res,2012,53(1-3): 41-57. |
[6] | WINKLER M S,RISSIEK A,PRIEFLER M,et al.Human leucocyte antigen (HLA-DR) gene expression is reduced in sepsis and correlates with impaired TNFα response: a diagnostic tool for immunosuppression?[J]. PLoS One,2017,12(8): e0182427. |
[7] | JUSKEWITCH J E,ABRAHAM R S,LEAGUE S C,et al.Monocyte HLA-DR expression and neutrophil CD64 expression as biomarkers of infection in critically ill neonates and infants[J]. Pediatr Res,2015,78(6): 683-690. |
[8] | FAIVRE V,LUKASZEWICZ A C,PAYEN D.Downregulation of blood monocyte HLA-DR in ICU patients is also present in bone marrow cells[J]. PLoS One,2016,11(11): e0164489. |
[9] | JÄMSÄ J,SYRJÄLÄ H,HUOTARI V,et al. Monocyte and lymphocyte surface molecules in severe sepsis and non-septic critically ill patients[J]. APMIS,2017,125(6): 536-543. |
[10] | 胡尧. 降钙素原在感染性疾病诊断和监测中的应用[J]. 检验医学,2017,32(3):234-239. |
[11] | 许程,徐元宏. 脓毒症早期预警生物标志物的研究进展[J]. 检验医学,2015,30(5):533-536. |
[12] | 杨喆娟,董慧慧,林志益,等. 乙型肝炎患者外周血单核细胞CD14+ CD16+亚群及HLA-DR的检测及其意义[J]. 放射免疫学杂志,2013,26(6):808-810. |
[13] | ZIEGLER-HEITBROCK L.The CD14+ CD16+ blood monocytes: their role in infection and inflammation[J]. J Leukoc Biol,2007,81(3): 584-592. |
[14] | INGERSOLL M A,PLATT A M,POTTEAUX S,et al.Monocyte trafficking in acute and chronic inflammation[J]. Trends Immunol,2011,32(10): 470-477. |
[15] | KIM O Y,MONSEL A,BERTRAND M,et al.Differential down-regulation of HLA-DR on monocyte subpopulations during systemic inflammation[J]. Crit Care,2010,14(2): R61. |
[16] | WEST S D,ZIEGLER A,BROOKS T,et al.An FcγRIIa polymorphism with decreased C-reactive protein binding is associated with sepsis and decreased monocyte HLA-DR expression in trauma patients[J]. J Trauma Acute Care Surg,2015,79(5): 773-781. |
[17] | CHO J H,YOON Y D,JANG H M,et al.Immunologic monitoring of T-lymphocyte subsets and Hla-Dr-positive monocytes in kidney transplant recipients: a prospective,observational cohort study[J]. Medicine (Baltimore),2015,94(44): e1902. |
[18] | DÖRING M,CABANILLAS STANCHI K M,HAUFE S,et al. Patterns of monocyte subpopulations and their surface expression of HLA-DR during adverse events after hematopoietic stem cell transplantation[J]. Ann Hematol,2015,94(5): 825-836. |
[1] | TANG Qingqin, QIAO Longwei, YIN Jingping, ZHANG Sheng, FENG Bin, LIANG Yuting. Correlation of peripheral blood monocyte count and serum anti-phospholipase A2 receptor antibody in patients with nephrotic syndrome [J]. Laboratory Medicine, 2023, 38(7): 647-652. |
[2] | HONG Jun, RAO Yongcai. Establishment and evaluation of CD157-based 4-color PNH assay for neutrophil and monocyte by flow cytometry [J]. Laboratory Medicine, 2022, 37(4): 377-381. |
[3] | SONG Yunxiao, TONG Wei, ZHANG Haichen, ZHANG Yinwang, BIAN Xiaobo, ZHANG Linlin, YUAN Wenhua, ZHAO Zhiyun, GE Wen, YAO Tianyue. Correlation of systemic inflammatory markers and fracture occurrence in elderly patients with osteoporosis [J]. Laboratory Medicine, 2022, 37(3): 235-239. |
[4] | WANG Tian, ZHAO Ming, GUAN Jiahao, FU Yawen, DANG Xiaojun. Distribution characteristics of neutrophil-to-lymphocyte ratio,platelet-to-lymphocyte ratio and lymphocyte-to-monocyte ratio of healthy adults in Xi’an [J]. Laboratory Medicine, 2022, 37(11): 1023-1025. |
[5] | ZHANG Yinwang, LIU Jinyu, SONG Yunxiao, GE Wen, ZHANG Linlin, YUAN Wenhua, ZHAO Zhiyun. Relationship between preoperative SII and postoperative infection in patients with open fracture after internal fixation [J]. Laboratory Medicine, 2022, 37(11): 1071-1074. |
[6] | WANG Xiaoqing, PENG Xuemei, LAN Meifeng, PAN Min. Evaluation of MCP-1 combined with CREWS for poor prognosis in patients with AECOPD [J]. Laboratory Medicine, 2022, 37(10): 934-938. |
[7] | CAI Qi, CHEN Liting, GUO Ping, LIN Han, WAN Yinglei. Application of leukocyte morphological parameters in the diagnosis of influenza A and B [J]. Laboratory Medicine, 2021, 36(6): 586-589. |
[8] | LI Junsheng, SONG Yunxiao, CHENG Jie. Roles of pretreatment PLR,NLR and LMR in the prognosis of prostate cancer [J]. Laboratory Medicine, 2021, 36(6): 631-636. |
[9] | CHEN Lijun, GAO Dandan, Lü Qianwen, XU Wei. Role of red blood cell distribution width and monocyte to lymphocyte ratio in ankylosing spondylitis [J]. Laboratory Medicine, 2019, 34(12): 1124-1127. |
[10] | DU Yan, LIU Hua, ZHANG Boke, LIU Yiwen, HE Yiqing, YANG Cuixia, ZHANG Guoliang, GAO Feng. Peripheral blood monocyte M2/M1 ratio for the diagnosis of breast cancer [J]. Laboratory Medicine, 2018, 33(5): 421-424. |
[11] | GAO Jijuan, FANG Huanying. Research progress in the relationship of apolipoprotein M with inflammatory diseases [J]. Laboratory Medicine, 2018, 33(3): 252-258. |
[12] | LIU Junfeng, JING Rui, LIU Yaning, HUO Qianyu, LIU Zhili, JIA Kegang, LI Yongshu, HAN Xuejing, LIN Wenhua, LIU Yunde. Correlation of the expressions of LOX-1 and CX3CR1 from monocytes and proximal/middle coronary artery stenosis [J]. Laboratory Medicine, 2017, 32(11): 1024-1030. |
[13] | LI Yongshu, ZHANG Baohuan, JIA Kegang, LIU Junfeng. CX3CL1 and CX3CR1 in lesion mechanism of atherosclerotic heart diseases [J]. Laboratory Medicine, 2016, 31(11): 1002-1010. |
[14] | LI Linyun, MEI Bing, WANG Changfu. Influence of different processing techniques on peripheral blood monocyte-platelet aggregation by flow cytometry [J]. Laboratory Medicine, 2015, 30(9): 916-920. |
[15] | WU Rongqiang, WANG Sujian, WANG Shizhong, ZHOU Haijun, QI Chunjian. The influence of beta-glucan on TNF-α,IL-8 and IL-12 in monocytes [J]. Laboratory Medicine, 2015, 30(3): 280-283. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||